MA32323B1 - Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques - Google Patents
Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiquesInfo
- Publication number
- MA32323B1 MA32323B1 MA33378A MA33378A MA32323B1 MA 32323 B1 MA32323 B1 MA 32323B1 MA 33378 A MA33378 A MA 33378A MA 33378 A MA33378 A MA 33378A MA 32323 B1 MA32323 B1 MA 32323B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- preparation
- sulfonamides
- heterocyclic
- oxadiazolone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, des procédés pour leur préparation et leur utilisation comme médicaments. La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone et leurs sels physiologiquement acceptables et leurs dérivés physiologiquement fonctionnels présentant une activité agoniste ppardelta ou ppardelta et pparalpha. L'invention concerne plus précisément des composés de formule i, dans laquelle les radicaux sont tels que définis, et leurs sels physiologiquement acceptables et des procédés pour leurs préparations. Les composés sont appropriés pour le traitement et/ou la prévention de troubles du métabolisme des acides gras et de troubles dans l'utilisation du glucose ainsi que de troubles dans lesquels l'insulino-résistance est impliquée et de troubles de démyélinisation et autres troubles neurodégénératifs du système nerveux central et périphérique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290572 | 2008-06-09 | ||
PCT/EP2009/003648 WO2009149820A1 (fr) | 2008-06-09 | 2009-05-22 | Sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, procédés pour leur préparation et leur utilisation comme médicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32323B1 true MA32323B1 (fr) | 2011-05-02 |
Family
ID=40219356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33378A MA32323B1 (fr) | 2008-06-09 | 2010-11-30 | Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques |
Country Status (19)
Country | Link |
---|---|
US (2) | US8329725B2 (fr) |
EP (1) | EP2288604B1 (fr) |
JP (1) | JP2011523664A (fr) |
KR (1) | KR20110023855A (fr) |
CN (1) | CN102056921A (fr) |
AR (1) | AR072013A1 (fr) |
AU (1) | AU2009256982A1 (fr) |
BR (1) | BRPI0914978A2 (fr) |
CA (1) | CA2727373A1 (fr) |
CL (1) | CL2009001365A1 (fr) |
IL (1) | IL209805A0 (fr) |
MA (1) | MA32323B1 (fr) |
MX (1) | MX2010013264A (fr) |
NZ (1) | NZ589694A (fr) |
RU (1) | RU2010154279A (fr) |
TW (1) | TW201011012A (fr) |
UY (1) | UY31872A (fr) |
WO (1) | WO2009149820A1 (fr) |
ZA (1) | ZA201007679B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2667545A1 (fr) * | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Composes de type oxadiazole et thiadiazole et leur utilisation comme modulateurs des recepteurs nicotiniques de l'acetylcholine |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2012064744A2 (fr) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tétrahydroquinoline et composés bicycliques associés pour l'inhibition de l'activité rorγ et le traitement de maladies |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
EP2847198B1 (fr) | 2012-05-08 | 2016-12-14 | Lycera Corporation | Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de ror-gamma et dans le traitement d'une maladie |
KR20150007300A (ko) | 2012-05-08 | 2015-01-20 | 머크 샤프 앤드 돔 코포레이션 | Ror감마 활성의 억제를 위한 테트라히드로나프티리딘 및 관련 비시클릭 화합물 및 질환의 치료 |
US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
WO2015095788A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie |
US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
AU2015222917A1 (en) | 2014-02-27 | 2016-09-15 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
WO2015171558A2 (fr) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie |
EP3140291A4 (fr) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Sulfonamide de tétrahydroquinoline et composés apparentés destinés à servir d'agonistes de rory et pour le traitement de maladies |
AU2016219183B2 (en) | 2015-02-11 | 2020-06-11 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
CA3002846A1 (fr) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Composes pyrazoles bicycliques substitues en tant qu'inhibiteurs de rorgammat et leurs utilisations |
CA3002850A1 (fr) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Composes indazole substitues utilises en tant qu'inhibiteurs de rorgammat et utilisations associees |
JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
CN110407721A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004513935A (ja) * | 2000-11-17 | 2004-05-13 | ノボ ノルディスク アクティーゼルスカブ | グルカゴンアンタゴニスト/逆アゴニスト |
DE10222034A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
DE10335450A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Ag | Indolin-Sulfanilsäureamide |
DE10335449A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Healthcare Ag | Bicyclische Indolinsulfonamid-Derivate |
SG138623A1 (en) | 2004-04-01 | 2008-01-28 | Aventis Pharmaceuticals Inc Us | Use of ppr delta agonists for treating demyelinating diseases |
DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
EP1932843A1 (fr) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments |
ES2427968T3 (es) * | 2008-07-14 | 2013-11-05 | Santen Pharmaceutical Co., Ltd | Nuevos derivados de indol que tienen un grupo carbamoilo, un grupo ureido y un grupo oxi sustituido |
WO2010090009A1 (fr) * | 2009-02-05 | 2010-08-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Dérivés d'indoline |
ES2481873T3 (es) * | 2010-05-12 | 2014-07-31 | Abbvie Inc. | Pirrolopiridina y pirrolopirimidina inhibidores de quinasas |
-
2009
- 2009-05-22 US US12/996,784 patent/US8329725B2/en not_active Expired - Fee Related
- 2009-05-22 WO PCT/EP2009/003648 patent/WO2009149820A1/fr active Application Filing
- 2009-05-22 KR KR1020107027641A patent/KR20110023855A/ko not_active Application Discontinuation
- 2009-05-22 BR BRPI0914978A patent/BRPI0914978A2/pt not_active Application Discontinuation
- 2009-05-22 AU AU2009256982A patent/AU2009256982A1/en not_active Abandoned
- 2009-05-22 CA CA2727373A patent/CA2727373A1/fr not_active Abandoned
- 2009-05-22 CN CN2009801216405A patent/CN102056921A/zh active Pending
- 2009-05-22 MX MX2010013264A patent/MX2010013264A/es unknown
- 2009-05-22 US US12/996,692 patent/US8946212B2/en not_active Expired - Fee Related
- 2009-05-22 NZ NZ589694A patent/NZ589694A/en not_active IP Right Cessation
- 2009-05-22 JP JP2011512853A patent/JP2011523664A/ja not_active Withdrawn
- 2009-05-22 EP EP09761383.0A patent/EP2288604B1/fr active Active
- 2009-05-22 RU RU2010154279/04A patent/RU2010154279A/ru unknown
- 2009-06-05 UY UY0001031872A patent/UY31872A/es not_active Application Discontinuation
- 2009-06-05 AR ARP090102028A patent/AR072013A1/es unknown
- 2009-06-05 CL CL2009001365A patent/CL2009001365A1/es unknown
- 2009-06-05 TW TW098118646A patent/TW201011012A/zh unknown
-
2010
- 2010-10-27 ZA ZA2010/07679A patent/ZA201007679B/en unknown
- 2010-11-30 MA MA33378A patent/MA32323B1/fr unknown
- 2010-12-06 IL IL209805A patent/IL209805A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009149820A1 (fr) | 2009-12-17 |
MX2010013264A (es) | 2011-02-25 |
US20110207738A1 (en) | 2011-08-25 |
US8329725B2 (en) | 2012-12-11 |
CN102056921A (zh) | 2011-05-11 |
NZ589694A (en) | 2012-05-25 |
US20120122853A1 (en) | 2012-05-17 |
EP2288604B1 (fr) | 2014-01-08 |
ZA201007679B (en) | 2011-07-27 |
AU2009256982A1 (en) | 2009-12-17 |
TW201011012A (en) | 2010-03-16 |
CL2009001365A1 (es) | 2010-11-05 |
US8946212B2 (en) | 2015-02-03 |
EP2288604A1 (fr) | 2011-03-02 |
KR20110023855A (ko) | 2011-03-08 |
BRPI0914978A2 (pt) | 2015-10-27 |
JP2011523664A (ja) | 2011-08-18 |
UY31872A (es) | 2010-01-29 |
AR072013A1 (es) | 2010-07-28 |
CA2727373A1 (fr) | 2009-12-17 |
IL209805A0 (en) | 2011-02-28 |
RU2010154279A (ru) | 2012-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32323B1 (fr) | Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques | |
MY148982A (en) | Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals | |
MA30981B1 (fr) | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments | |
US9926299B2 (en) | Inhibitors of bruton's tyrosine kinase | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
MX2010006647A (es) | Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
BRPI0509517A (pt) | derivados de oxadiazolona como agonistas de ppar delta | |
MA30411B1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
MA35191B1 (fr) | Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2 | |
JP6636060B2 (ja) | 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体 | |
MA27741A1 (fr) | Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments | |
MA37691B1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
CN112384220A (zh) | sGC刺激剂治疗线粒体障碍的用途 | |
MA37763B1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
NO20081681L (no) | N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika | |
TW200500349A (en) | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
MA29812B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques | |
WO2007039174A3 (fr) | [1,3,4]-thiadiazol-2-yl-amides bicycliques de l'acide aryl-sulfonique, leurs procedes de preparation, et leur utilisation en tant que substances pharmaceutiques | |
MY148883A (en) | Derivatives of 2-aminothiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals | |
US9796722B1 (en) | Hepatitis B viral assembly effectors | |
US20220047587A1 (en) | Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio | |
MY140251A (en) | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals |